Comparing HIV Drug Resistance Tests: The CREST Study
Author Information
Author(s): Hales Gillian, Birch Chris, Crowe Suzanne, Workman Cassy, Hoy Jennifer F, Law Matthew G, Kelleher Anthony D, Lincoln Douglas, Emery Sean
Primary Institution: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales
Hypothesis
Does providing a virtual phenotype report in addition to a genotype report improve clinical outcomes for patients changing their HIV treatment?
Conclusion
The study suggests that using genotyping alone is sufficient for managing HIV infection, as there were no significant benefits from adding virtual phenotype testing.
Supporting Evidence
- 327 patients completed more than one month of follow-up.
- Resistance tests were the primary means by which ART regimens were selected.
- At 48 weeks, there were no significant differences in HIV RNA levels between the two groups.
Takeaway
This study looked at two types of tests to see which helps doctors choose better HIV treatments. It found that just one test is good enough.
Methodology
Randomised, open-label trial with 48-week follow-up involving patients changing their antiretroviral therapy.
Potential Biases
No evidence of selection bias was found, but the interpretation of results may be influenced by the test method used.
Limitations
The trial did not directly compare the two testing platforms and may not reflect current resistance cutoffs.
Participant Demographics
Patients were HIV-infected adults over 18 years old, with a history of ART and plasma HIV RNA > 2000 copies/mL.
Statistical Information
P-Value
p = 0.23
Statistical Significance
p = 0.32
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website